Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.
Fayad A, Principi I, Balestracci A, Alconcher L, Coccia P, Adragna M, Amoreo O, Bettendorff MC, Blumetti MV, Bonany P, Tonfi MLF, Flynn L, Ghezzi L, Montero J, Ramírez F, Seminara C, Suarez Á, Spizzirri AP, Rivas M, Pichel M, Zylberman V, Spatz L, Massa C, Valerio M, Sanguineti S, Colonna M, Roubicek I, Goldbaum F; INM004 Study Group.
Fayad A, et al. Among authors: ramirez f.
Pediatr Nephrol. 2024 Nov 12. doi: 10.1007/s00467-024-06583-3. Online ahead of print.
Pediatr Nephrol. 2024.
PMID: 39528845